 | |
| Clinical data | |
|---|---|
| Other names | CVL-871; CVL871; PF-06669571; PF06669571; PF-6669571; PF6669571; PW-0464; PW0464 |
| Routes of administration | Oral[1] |
| Drug class | Dopamine receptor agonist;DopamineD1 andD5 receptoragonist |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C19H17F2N3O4 |
| Molar mass | 389.359 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Razpipadon (developmental codesCVL-871,PF-06669571, andPW-0464) is adopamine receptor agonist which is under development for the treatment ofdementia-related apathy.[1][2][3][4] It is takenorally.[1]
Razpipadon acts as aselectivepartial agonist of thedopamineD1 andD5 receptors.[1][2][5]
The drug was originated byPfizer and is under development byCerevel Therapeutics.[1] As of April 2022, razpipadon is inphase 2clinical trials for dementia-related apathy.[1]
 | Thisdrug article relating to thenervous system is astub. You can help Wikipedia byadding missing information. |